Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Assertio Holdings, Inc.NASDAQ: ASRT

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow turns positive

Q1 FY2026 investing cash flow was $15.11M, compared with -$2.94M a year earlier. Trailing-twelve-month investing cash flow was $6.06M. Over 3 fiscal years it compounded at -34.5% a year.

Context

  • Investing cash flow amounted to 10.1% of revenue in FY2025, down 29.0 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near $15.11M or moves back toward the trailing-twelve-month quarterly average of $1.51M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.11M+789.3% QoQ
Last fiscal yearDec 2025
-$11.99M-75.5% YoY
LTMMar 2026
$6.06M+111.7% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+614.8%——
1 year-75.5%——
3-year CAGR-34.5%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(11.99M) USD
Year-over-year change
+75.5%

Investing Cash Flow vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +111.7% is the 5th highest of 10, against a peer median of +105.8%.
  • Investing cash flow amounts to 5.9% of revenue for ASRT, versus a peer median of 7.7%.
ASRT Competitors
Investing Cash Flow for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$95.77M USD+227.3%—1048.3%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$62.28M USD+11.4%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$60.01M USD+256.3%——
LUNGPulmonx CorporationLTM Mar 2026$14.16M USD-61.0%—16.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$8.96M USD+164.7%—13.5%
ASRTAssertio Holdings, Inc.LTM Mar 2026$6.06M USD+111.7%-34.5%5.9%
INCRInterCure Ltd.LTM Jun 2025₪4.33M ILS-139.2%-75.9%1.8%
VXRTVaxart, Inc.LTM Mar 2026$2.72M USD+188.8%—1.1%
XBITXBiotech Inc.LTM Mar 2026$186K USD-83.7%-83.5%—
NTRBNutriband Inc.LTM Apr 2026$5.32K USD+105.8%-59.4%0.3%
Peer median (excluding ASRT) —+105.8%-75.9%7.7%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Depreciation & Amortization29.08M33.4M28.23M25.83M30.01M
Deferred Income Tax0(80.38M)76.2M00
Stock-Based Compensation3.55M7.5M9.16M5.01M3.45M
Change in Working Capital(31.29M)(13.01M)140K5.2M(45.33M)
Accounts Receivables(11K)(996K)48.67M(6.46M)(65.99M)
Inventory4.27M(6.59M)(4.97M)(9.58M)9.68M
Accounts Payables(28.7M)(10.11M)(29.35M)(1.26M)(13.29M)
Other Working Capital(6.85M)4.69M(14.21M)22.5M24.27M
Other Non-Cash Items5.48M21.46M267.82M11.95M14.07M
Operating Cash Flow5.52M78.6M49.6M26.41M(28.18M)
Capital Expenditures(53K)(274K)(628K)00
Acquisitions (Net)(18.47M)(42.4M)1.53M00
Purchases of Investments000(98.61M)(119.2M)
Sales of Investments002.19M49.69M115.38M
Other Investing Activities0000(8.17M)
Investing Cash Flow(18.53M)(42.67M)3.1M(48.91M)(11.99M)
Debt Repayment(9.84M)(750K)(10.5M)00
Common Stock Issued44.86M7.02M000
Common Stock Repurchased(418K)(838K)(7.9M)(350K)0
Dividends Paid00000
Other Financing Activities(5.58M)(13.23M)(25.8M)0(189K)
Financing Cash Flow29.03M(7.79M)(44.2M)(350K)(189K)
Effect of Forex Changes00000
Net Change in Cash16.02M28.13M8.5M(22.85M)(40.36M)
Free Cash Flow5.47M78.32M48.98M26.41M(28.18M)

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.